Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Buys NextGen's Electrophoresis Business

NEW YORK (GenomeWeb News) – NextGen Sciences said today that it has sold its electrophoresis business to Sigma-Aldrich for an undisclosed sum.

The Ann Arbor, Mich.-based company said the deal is part of its strategic realignment plan to pare back its operations and focus on its biomarker services.

Under this agreement, Sigma-Aldrich has acquired NextGen's automated gel casting unit, the a2DEoptimizer, and its large format pre-cast gels for a cash payment and royalties based on revenues over three years.

Sigma-Aldrich will focus its efforts primarily on supplying the optigels to customers in Europe and North America.

NextGen said in April 2008 that it would seek to divest or wind down its software and instrumentation UK-based businesses and focus all of its resources on biomarker services, which include discovery, assay development, and testing.

NextGen licensed its expressionfactory, expressionworkstation, and the orchestratorIMS software suite to eXeTek, a NextGen spinout company, in December.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.